[1] Lim H, Devesa SS, Sosa JA, et al.  Trends in thyroid cancer incidence and mortality in the United States, 1974−2013[J]. JAMA, 2017, 317(13): 1338-1348.   doi: 10.1001/jama.2017.2719
[2] Hovens GC, Stokkel MP, Kievit J, et al.  Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2007, 92(7): 2610-2615.   doi: 10.1210/jc.2006-2566
[3] 中华医学会核医学分会.  131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
Chinese Society of Nuclear Medicine.  Clinical guidelines for 131I treatment of differentiated thyroid cancer (2014 Edition)[J]. Chin J Nucl Med Mol Imaging, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
[4] Haugen BR, Alexander EK, Bible KC, et al.  2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[5] Kotwal A, Cortes T, Genere N, et al.  Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2020, 105(12): 3683-3694.   doi: 10.1210/clinem/dgaa672
[6] Biondi B, Cooper DS.  The clinical significance of subclinical thyroid dysfunction[J]. Endocr Rev, 2008, 29(1): 76-131.   doi: 10.1210/er.2006-0043
[7] Cao CD, Wémeau JL.  Risk-benefit ratio for TSH-suppressive levothyroxine therapy in differentiated thyroid cancer[J]. Ann Endocrinol, 2015, 76(1S1): S47-52.   doi: 10.1016/S0003-4266(16)30014-2
[8] Singh S, Duggal J, Molnar J, et al.  Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis[J]. Int J Cardiol, 2008, 125(1): 41-48.   doi: 10.1016/j.ijcard.2007.02.027
[9]

Paragliola RM, Di Donna V, Locantore P, et al. Factors predicting time to TSH normalization and persistence of TSH suppression after total thyroidectomy for Graves' disease[J/OL]. Front Endocrinol, 2019, 10: 95[2021-11-30]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405427. DOI: 10.3389/fendo.2019.00095.
[10]

Miccoli P, Materazzi G, Rossi L. Levothyroxine therapy in thyrodectomized patients[J/OL]. Front Endocrinol (Lausanne), 2021, 11: 626268[2021-11-30]. https://pubmed.ncbi.nlm.nih.gov/33584551. DOI: 10.3389/fendo.2020.626268.
[11]

Benvenga S. L-T4 therapy in the presence of pharmacological interferents[J/OL]. Front Endocrinol (Lausanne), 2020, 11: 607446[2021-11-30]. https://pubmed.ncbi.nlm.nih.gov/33414765. DOI: 10.3389/fendo.2020.607446.
[12] Jonklaas J.  Sex and age differences in levothyroxine dosage requirement[J]. Endocr Pract, 2010, 16(1): 71-79.   doi: 10.4158/EP09257.OR
[13] Liwanpo L, Hershman JM.  Conditions and drugs interfering with thyroxine absorption[J]. Best Pract Res Clin Endocrinol Metab, 2009, 23(6): 781-792.   doi: 10.1016/j.beem.2009.06.006
[14] Di Donna V, Santoro MG, de Waure C, et al.  A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease[J]. Thyroid, 2014, 24(12): 1759-1764.   doi: 10.1089/thy.2014.0111
[15] Zaborek NA, Cheng A, Imbus JR, et al.  The optimal dosing scheme for levothyroxine after thyroidectomy: a comprehensive comparison and evaluation[J]. Surgery, 2019, 165(1): 92-98.   doi: 10.1016/j.surg.2018.04.097
[16] Chen SS, Zaborek NA, Doubleday AR, et al.  Optimizing levothyroxine dose adjustment after thyroidectomy with a decision tree[J]. J Surg Res, 2019, 244: 102-106.   doi: 10.1016/j.jss.2019.06.025
[17] 李林通, 计成, 严思敏, 等.  分化型甲状腺癌患者术后左甲状腺素最佳初始剂量预测模型探讨[J]. 中国药房, 2019, 30(3): 387-391.   doi: 10.6039/j.issn.1001-0408.2019.03.21
Li LT, Ji C, Yan SM, et al.  Investigation of prediction model for optimal initial dose of levothyroxine in differentiated thyroid cancer patients after surgery[J]. China Pharm, 2019, 30(3): 387-391.   doi: 10.6039/j.issn.1001-0408.2019.03.21